NCT06007924View on ClinicalTrials.gov

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 16, 2023

Primary Completion Date

August 16, 2027

Study Completion Date

August 16, 2027

Conditions
Thyroid Cancer
Interventions
DRUG

Avutometinib

Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off

DRUG

Defactinib

Defactinib 200 mg twice daily 3 weeks on/1 week off

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack

18103

RECRUITING

Lehigh Valley Health Network (Data Collection Only), Allentown

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER